{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:47:05Z","timestamp":1790408825431,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T00:00:00Z","timestamp":1621900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T00:00:00Z","timestamp":1621900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"U.S President's Malaria Initiative","award":["GHS-A-00-09-00003-00"],"award-info":[{"award-number":["GHS-A-00-09-00003-00"]}]},{"name":"NIAID International center of Excellence in Malaria Research","award":["ICEMR NIAID U19 AI 089696"],"award-info":[{"award-number":["ICEMR NIAID U19 AI 089696"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The current first-line treatments for uncomplicated malaria recommended by the National Malaria Control Programme in Mali are artemether\u2013lumefantrine (AL) and artesunate\u2013amodiaquine (ASAQ). From 2015 to 2016, an in vivo study was carried out to assess the clinical and parasitological responses to AL and ASAQ in S\u00e9lingu\u00e9, Mali.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Children between 6 and 59\u00a0months of age with uncomplicated <jats:italic>Plasmodium falciparum<\/jats:italic> infection and 2000\u2013200,000 asexual parasites\/\u03bcL of blood were enrolled, randomly assigned to either AL or ASAQ, and followed up for 42\u00a0days. Uncorrected and PCR-corrected efficacy results at days 28 and 42. were calculated. Known markers of resistance in the <jats:italic>Pfk13, Pfmdr1,<\/jats:italic> and <jats:italic>Pfcrt<\/jats:italic> genes were assessed using Sanger sequencing.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 449 patients were enrolled: 225 in the AL group and 224 in the ASAQ group. Uncorrected efficacy at day 28 was 83.4% (95% CI 78.5\u201388.4%) in the AL arm and 93.1% (95% CI 89.7\u201396.5%) in the ASAQ arm. The per protocol PCR-corrected efficacy at day 28 was 91.0% (86.0\u201395.9%) in the AL arm and 97.1% (93.6\u2013100%) in the ASAQ arm. ASAQ was significantly (p\u2009&lt;\u20090.05) better than AL for each of the aforementioned efficacy outcomes. No mutations associated with artemisinin resistance were identified in the <jats:italic>Pfk13<\/jats:italic> gene. Overall, for <jats:italic>Pfmdr1<\/jats:italic>, the N86 allele and the N<jats:bold>F<\/jats:bold>D haplotype were the most common. The N<jats:bold>F<\/jats:bold>D haplotype was significantly more prevalent in the post-treatment than in the pre-treatment isolates in the AL arm (p\u2009&lt;\u20090.01) but not in the ASAQ arm. For <jats:italic>Pfcrt<\/jats:italic>, the CV<jats:bold>IET<\/jats:bold> haplotype was the most common.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The findings indicate that both AL and ASAQ remain effective for the treatment of uncomplicated malaria in S\u00e9lingu\u00e9, Mali.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12936-021-03760-9","type":"journal-article","created":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T08:02:57Z","timestamp":1621929777000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Therapeutic efficacy of artemether\u2013lumefantrine and artesunate\u2013amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Mali, 2015\u20132016"],"prefix":"10.1186","volume":"20","author":[{"given":"Youssouf","family":"Diarra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oumar","family":"Kon\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lansana","family":"Sangar\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lassina","family":"Doumbia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dade Bouye Ben","family":"Haidara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mouctar","family":"Diallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ababacar","family":"Maiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamadoun A.","family":"Sango","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halidou","family":"Sidib\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jules","family":"Mihigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Nace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragan","family":"Ljolje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eldin","family":"Talundzic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkatachalam","family":"Udhayakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Eckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia J.","family":"Woodfill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah F.","family":"Moriarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pharath","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald J.","family":"Krogstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric S.","family":"Halsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi W.","family":"Lucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6535-3323","authenticated-orcid":false,"given":"Ousmane A.","family":"Koita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,25]]},"reference":[{"key":"3760_CR1","volume-title":"World malaria report 2019","author":"WHO","year":"2019","unstructured":"WHO. World malaria report 2019. Geneva: World Health Organization; 2019."},{"key":"3760_CR2","unstructured":"INFO-STAT, INSTAT, ICF International. Enqu\u00eate D\u00e9mographique et de Sant\u00e9 du Mali EDSM-V 2012\u20132013. Rapport Pr\u00e9liminaire. Mali; 2013 p. 43. https:\/\/dhsprogram.com\/pubs\/pdf\/PR33\/PR33.pdf"},{"issue":"Suppl 1","key":"3760_CR3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.4269\/ajtmh.2001.64.12","volume":"64","author":"J Trape","year":"2001","unstructured":"Trape J. The public health impact of chloroquine resistance in Africa. Am J Trop Med Hyg. 2001;64(Suppl 1):12\u20137.","journal-title":"Am J Trop Med Hyg"},{"key":"3760_CR4","volume-title":"Guidelines for the treatment of malaria","author":"WHO","year":"2015","unstructured":"WHO. Guidelines for the treatment of malaria. Geneva: World Health Organization; 2015."},{"key":"3760_CR5","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1056\/NEJMoa0808859","volume":"361","author":"AM Dondorp","year":"2009","unstructured":"Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361:455\u201367.","journal-title":"N Engl J Med"},{"key":"3760_CR6","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1314981","volume":"371","author":"EA Ashley","year":"2014","unstructured":"Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371:411\u201323.","journal-title":"N Engl J Med"},{"key":"3760_CR7","doi-asserted-by":"publisher","first-page":"e02655","DOI":"10.1128\/AAC.02655-16","volume":"61","author":"SM Chenet","year":"2017","unstructured":"Chenet SM, Okoth SA, Kelley J, Lucchi N, Huber CS, Vreden S, et al. Molecular profile of malaria drug resistance markers of Plasmodium falciparum in Suriname. Antimicrob Agents Chemother. 2017;61:e02655-e2716.","journal-title":"Antimicrob Agents Chemother"},{"key":"3760_CR8","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1038\/s41591-020-1005-2","volume":"26","author":"A Uwimana","year":"2020","unstructured":"Uwimana A, Legrand E, Stokes BH, Ndikumana J-LM, Warsame M, Umulisa N, et al. Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda. Nat Med. 2020;26:1602\u20138.","journal-title":"Nat Med."},{"key":"3760_CR9","doi-asserted-by":"publisher","first-page":"634","DOI":"10.4269\/ajtmh.15-0503","volume":"94","author":"P Ringwald","year":"2016","unstructured":"Ringwald P, Guindo CO, Niar\u00e9 K, Benoit-Vical F, Coulibaly CO, Djimd\u00e9 AA, et al. In vivo efficacy and parasite clearance of artesunate + sulfadoxine\u2013pyrimethamine versus artemether\u2013lumefantrine in Mali. Am J Trop Med Hyg. 2016;94:634\u20139.","journal-title":"Am J Trop Med Hyg"},{"key":"3760_CR10","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.4269\/ajtmh.16-0053","volume":"95","author":"B Dieye","year":"2016","unstructured":"Dieye B, Affara M, Sangare L, Joof F, Ndiaye YD, Gomis JF, et al. West Africa International Centers of Excellence for Malaria Research: drug resistance patterns to artemether\u2013lumefantrine in Senegal, Mali, and The Gambia. Am J Trop Med Hyg. 2016;95:1054\u201360.","journal-title":"Am J Trop Med Hyg"},{"key":"3760_CR11","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1186\/s12936-018-2496-x","volume":"17","author":"S Dama","year":"2018","unstructured":"Dama S, Niangaly H, Djimde M, Sagara I, Guindo CO, Zeguime A, et al. A randomized trial of dihydroartemisinin\u2013piperaquine versus artemether\u2013lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali. Malar J. 2018;17:347.","journal-title":"Malar J"},{"issue":"14","key":"3760_CR12","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12916-016-0716-1","volume":"24","author":"L Denoeud-Ndam","year":"2016","unstructured":"Denoeud-Ndam L, Dicko A, Baudin E, Guindo O, Grandesso F, Diawara H, et al. Efficacy of artemether-lumefantrine in relation to drug exposure in children with and without severe acute malnutrition: an open comparative intervention study in Mali and Niger. BMC Med. 2016;24(14):167.","journal-title":"BMC Med"},{"key":"3760_CR13","doi-asserted-by":"publisher","first-page":"50","DOI":"10.4269\/ajtmh.2012.11-0649","volume":"87","author":"I Sagara","year":"2012","unstructured":"Sagara I, Fofana B, Gaudart J, Sidibe B, Togo A, Toure S, et al. Repeated artemisinin-based combination therapies in a malaria hyperendemic area of Mali: efficacy, safety, and public health impact. Am J Trop Med Hyg. 2012;87:50\u20136.","journal-title":"Am J Trop Med Hyg"},{"key":"3760_CR14","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S1473-3099(15)00318-7","volume":"16","author":"I Sagara","year":"2016","unstructured":"Sagara I, Beavogui AH, Zongo I, Soulama I, Borghini-Fuhrer I, Fofana B, et al. Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial. Lancet Infect Dis. 2016;16:189\u201398.","journal-title":"Lancet Infect Dis"},{"key":"3760_CR15","unstructured":"WHO. Status report on artemisinin resistance and ACT efficacy (August 2018) [Internet]. Geneva, World Health Organization; 2018. http:\/\/www.who.int\/malaria\/publications\/atoz\/artemisinin-resistance-august2018\/en\/"},{"key":"3760_CR16","unstructured":"WHO. Report on antimalarial drug efficacy, resistance and response: 10 years of surveillance (2010\u20132019) https:\/\/www.who.int\/publications-detail-redirect\/9789240012813. Accessed 26 Mar 2021"},{"key":"3760_CR17","doi-asserted-by":"crossref","unstructured":"Venkatesan M, Gadalla NB, Stepniewska K, Dahal P, Nsanzabana C, Moriera C, et al. Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. Am J Trop Med Hyg. 2014;91:833\u201343.","DOI":"10.4269\/ajtmh.14-0031"},{"key":"3760_CR18","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1056\/NEJM200101253440403","volume":"344","author":"A Djimd\u00e9","year":"2001","unstructured":"Djimd\u00e9 A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourt\u00e9 Y, et al. A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med. 2001;344:257\u201363.","journal-title":"N Engl J Med"},{"key":"3760_CR19","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1475-2875-8-34","volume":"8","author":"M Tekete","year":"2009","unstructured":"Tekete M, Djimde AA, Beavogui AH, Maiga H, Sagara I, Fofana B, et al. Efficacy of chloroquine, amodiaquine and sulphadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria: revisiting molecular markers in an area of emerging AQ and SP resistance in Mali. Malar J. 2009;8:34.","journal-title":"Malar J"},{"key":"3760_CR20","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1186\/s12936-016-1503-3","volume":"15","author":"SD Otienoburu","year":"2016","unstructured":"Otienoburu SD, Ma\u00efga-Ascofar\u00e9 O, Schramm B, Jullien V, Jones JJ, Zolia YM, et al. Selection of Plasmodium falciparum pfcrt and pfmdr1 polymorphisms after treatment with artesunate\u2013amodiaquine fixed dose combination or artemether\u2013lumefantrine in Liberia. Malar J. 2016;15:452.","journal-title":"Malar J"},{"key":"3760_CR21","doi-asserted-by":"publisher","first-page":"455","DOI":"10.4269\/ajtmh.2008.78.455","volume":"78","author":"AA Djimd\u00e9","year":"2008","unstructured":"Djimd\u00e9 AA, Fofana B, Sagara I, Sidibe B, Toure S, Dembele D, et al. Efficacy, safety, and selection of molecular markers of drug resistance by two ACTs in Mali. Am J Trop Med Hyg. 2008;78:455\u201361.","journal-title":"Am J Trop Med Hyg"},{"key":"3760_CR22","doi-asserted-by":"publisher","first-page":"e0151565","DOI":"10.1371\/journal.pone.0151565","volume":"11","author":"P Sondo","year":"2016","unstructured":"Sondo P, Derra K, Diallo Nakanabo S, Tarnagda Z, Kazienga A, Zampa O, et al. Artesunate-amodiaquine and artemether-lumefantrine therapies and selection of Pfcrt and Pfmdr1 alleles in Nanoro, Burkina Faso. PLoS ONE. 2016;11:e0151565.","journal-title":"PLoS ONE."},{"key":"3760_CR23","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s12936-016-1251-4","volume":"15","author":"M Tour\u00e9","year":"2016","unstructured":"Tour\u00e9 M, Sanogo D, Dembele S, Diawara SI, Oppfeldt K, Schi\u00f8ler KL, et al. Seasonality and shift in age-specific malaria prevalence and incidence in Binko and Carri\u00e8re villages close to the lake in Selingu\u00e9. Mali Malar J. 2016;15:219.","journal-title":"Mali Malar J"},{"key":"3760_CR24","volume-title":"Methods for surveillance of antimalarial drug efficacy","author":"WHO","year":"2009","unstructured":"WHO. Methods for surveillance of antimalarial drug efficacy. Geneva: World Health Organization; 2009."},{"key":"3760_CR25","first-page":"621","volume":"66","author":"D Payne","year":"1988","unstructured":"Payne D. Use and limitations of light microscopy for diagnosing malaria at the primary health care level. Bull World Health Organ. 1988;66:621\u20136.","journal-title":"Bull World Health Organ"},{"key":"3760_CR26","volume-title":"Methods and techniques for clinical trials on antimalarial drug efficacy","author":"WHO","year":"2009","unstructured":"WHO. Methods and techniques for clinical trials on antimalarial drug efficacy. Geneva: World Health Organization; 2009."},{"key":"3760_CR27","unstructured":"Manual size estimation of msp1, msp2 and glurp PCR products on gel [Internet]. Worldwide Antimalarial Resistance Network. 2014. https:\/\/www.wwarn.org\/tools-resources\/procedures\/manual-size-estimation-msp1-msp2-and-glurp-pcr-products-gel. Accessed 9 Jun 2020."},{"key":"3760_CR28","doi-asserted-by":"publisher","first-page":"e1004789","DOI":"10.1371\/journal.ppat.1004789","volume":"11","author":"E Talundzic","year":"2015","unstructured":"Talundzic E, Okoth SA, Congpuong K, Plucinski MM, Morton L, Goldman IF, et al. Selection and spread of artemisinin-resistant alleles in Thailand prior to the global artemisinin resistance containment campaign. PLoS Pathog. 2015;11:e1004789.","journal-title":"PLoS Pathog."},{"key":"3760_CR29","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/1475-2875-12-103","volume":"12","author":"M Malmberg","year":"2013","unstructured":"Malmberg M, Ngasala B, Ferreira PE, Larsson E, Jovel I, Hjalmarsson A, et al. Temporal trends of molecular markers associated with artemether-lumefantrine tolerance\/resistance in Bagamoyo district. Tanzania Malar J. 2013;12:103.","journal-title":"Tanzania Malar J"},{"key":"3760_CR30","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.3201\/eid2313.170366","volume":"23","author":"ES Halsey","year":"2017","unstructured":"Halsey ES, Venkatesan M, Plucinski MM, Talundzic E, Lucchi NW, Zhou Z, et al. Capacity development through the US President\u2019s Malaria Initiative-Supported Antimalarial Resistance Monitoring in Africa Network. Emerg Infect Dis. 2017;23:S53-56.","journal-title":"Emerg Infect Dis"},{"key":"3760_CR31","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/S1473-3099(17)30365-1","volume":"17","author":"OA Koita","year":"2017","unstructured":"Koita OA, Sangar\u00e9 L, Miller HD, Sissako A, Coulibaly M, Thompson TA, et al. AQ-13, an investigational antimalarial, versus artemether plus lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria: a randomised, phase 2, non-inferiority clinical trial. Lancet Infect Dis. 2017;17:1266\u201375.","journal-title":"Lancet Infect Dis"},{"key":"3760_CR32","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/tmi.12274","volume":"19","author":"H Tinto","year":"2014","unstructured":"Tinto H, Diallo S, Zongo I, Guiraud I, Valea I, Kazienga A, et al. Effectiveness of artesunate-amodiaquine vs. artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in Nanoro, Burkina Faso: a non-inferiority randomised trial. Trop Med Int Health. 2014;19:469\u201375.","journal-title":"Trop Med Int Health."},{"key":"3760_CR33","doi-asserted-by":"publisher","first-page":"634","DOI":"10.4269\/ajtmh.15-0503","volume":"94","author":"K Niar\u00e9","year":"2016","unstructured":"Niar\u00e9 K, Dara A, Sagara I, Sissoko MS, Guindo CO, Ciss\u00e9 NH, et al. In vivo efficacy and parasite clearance of artesunate + sulfadoxine\u2013pyrimethamine versus artemether\u2013lumefantrine in Mali. Am J Trop Med Hyg. 2016;94:634\u20139.","journal-title":"Am J Trop Med Hyg"},{"key":"3760_CR34","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1186\/s12936-018-2496-x","volume":"17","author":"S Dama","year":"2018","unstructured":"Dama S, Niangaly H, Djimde M, Sagara I, Guindo CO, Zeguime A, et al. A randomized trial of dihydroartemisinin-piperaquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali. Malar J. 2018;17:347.","journal-title":"Malar J"},{"key":"3760_CR35","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1093\/infdis\/jiy637","volume":"219","author":"A Yeka","year":"2019","unstructured":"Yeka A, Wallender E, Mulebeke R, Kibuuka A, Kigozi R, Bosco A, et al. Comparative efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated malaria in Ugandan Children. J Infect Dis. 2019;219:1112\u201320.","journal-title":"J Infect Dis"},{"key":"3760_CR36","doi-asserted-by":"publisher","first-page":"e01949","DOI":"10.1128\/AAC.00338-21","volume":"65","author":"PR Dimbu","year":"2021","unstructured":"Dimbu PR, Horth R, C\u00e2ndido ALM, Ferreira CM, Caquece F, Garcia LEA, et al. Continued Low efficacy of artemether-lumefantrine in Angola in 2019. Antimicrob Agents Chemother. 2021;65:e01949-e2020.","journal-title":"Antimicrob Agents Chemother"},{"key":"3760_CR37","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12936-021-03585-6","volume":"20","author":"A Gansan\u00e9","year":"2021","unstructured":"Gansan\u00e9 A, Moriarty LF, M\u00e9nard D, Yerbanga I, Ouedraogo E, Sondo P, et al. Anti-malarial efficacy and resistance monitoring of artemether-lumefantrine and dihydroartemisinin-piperaquine shows inadequate efficacy in children in Burkina Faso, 2017\u20132018. Malar J. 2021;20:48.","journal-title":"Malar J"},{"key":"3760_CR38","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1093\/infdis\/jiu467","volume":"211","author":"SM Taylor","year":"2015","unstructured":"Taylor SM, Parobek CM, De Conti DK, Kayentao K, Coulibaly SO, Greenwood BM, et al. Absence of putative artemisinin resistance mutations among Plasmodium falciparum in sub-Saharan Africa: a molecular epidemiologic study. J Infect Dis. 2015;211:680\u20138.","journal-title":"J Infect Dis"},{"key":"3760_CR39","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1056\/NEJMoa1513137","volume":"374","author":"D M\u00e9nard","year":"2016","unstructured":"M\u00e9nard D, Khim N, Beghain J, Adegnika AA, Shafiul-Alam M, Amodu O, et al. A Worldwide map of Plasmodium falciparum K13-propeller polymorphisms. N Engl J Med. 2016;374:2453\u201364.","journal-title":"N Engl J Med"},{"key":"3760_CR40","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1128\/AAC.00968-08","volume":"53","author":"CT Happi","year":"2009","unstructured":"Happi CT, Gbotosho GO, Folarin OA, Sowunmi A, Hudson T, O\u2019Neil M, et al. Selection of Plasmodium falciparum multidrug resistance gene 1 alleles in asexual stages and gametocytes by artemether-lumefantrine in Nigerian children with uncomplicated falciparum malaria. Antimicrob Agents Chemother. 2009;53:888\u201395.","journal-title":"Antimicrob Agents Chemother"},{"key":"3760_CR41","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1186\/s12936-019-2986-5","volume":"18","author":"SAS Diakit\u00e9","year":"2019","unstructured":"Diakit\u00e9 SAS, Traor\u00e9 K, Sanogo I, Clark TG, Campino S, Sangar\u00e9 M, et al. A comprehensive analysis of drug resistance molecular markers and Plasmodium falciparum genetic diversity in two malaria endemic sites in Mali. Malar J. 2019;18:361.","journal-title":"Malar J"},{"key":"3760_CR42","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.meegid.2011.01.003","volume":"11","author":"JB Lekana-Douki","year":"2011","unstructured":"Lekana-Douki JB, Boutamba SDD, Zatra R, Edou SEZ, Ekomy H, Bisvigou U, et al. Increased prevalence of the Plasmodium falciparum Pfmdr1 86N genotype among field isolates from Franceville, Gabon after replacement of chloroquine by artemether\u2013lumefantrine and artesunate\u2013mefloquine. Infect Genet Evol. 2011;11:512\u20137.","journal-title":"Infect Genet Evol"},{"key":"3760_CR43","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12936-019-2716-z","volume":"18","author":"M Ocan","year":"2019","unstructured":"Ocan M, Akena D, Nsobya S, Kamya MR, Senono R, Kinengyere AA, et al. Persistence of chloroquine resistance alleles in malaria endemic countries: a systematic review of burden and risk factors. Malar J. 2019;18:76.","journal-title":"Malar J"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-021-03760-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-021-03760-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-021-03760-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T08:07:19Z","timestamp":1621930039000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-021-03760-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,25]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3760"],"URL":"https:\/\/doi.org\/10.1186\/s12936-021-03760-9","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,25]]},"assertion":[{"value":"20 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors have given their consent for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"235"}}